Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis Published JANUARY 01, 2020

https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30453-X/fulltext

Before Covid or Ivermectin was a political issue it was shown as safe for pregnant women at normal doses and safe for others at at least 10x recommended dose

"This study was sponsored by a grant from Merck Research Laboratories, a division ofMerck & Co., Inc"

https://pubmed.ncbi.nlm.nih.gov/12362927/

Download full PDF study from webarchive

https://web.archive.org/web/20210719231037/https://sci-hub.st/10.1177/009127002237994

"Ivermectin was generally well tolerated, with no indication of associated CNS toxicity for doses up to 10 times the highest FDA‐approved dose of 200 μg/kg.

All dose regimens had a mydriatic effect similar to placebo.

Adverse experiences were similar between ivermectin and placebo and did not increase with dose."

Journal of Clinical Pharmacology, 2002;42:1122-1133 ©2002 the American College of Clinical Pharmacology

"This study demonstrated that ivermectin is generally well tolerated at these higher doses and more frequent regimens."

"In summary, the safety profile generated in this study supports the use of oral ivermectin at the approved dose levels and at dose levels being considered for the treatment of head lice. Furthermore, a significant safety margin is demonstrated. However, studies in the pediatric population are necessary to confirm safety in children at higher dose levels.

The pharmacokinetic parameters are consistent with those previously established, with the exception of a slightly longer half-life. A significant food interaction was demonstrated.

We would like to acknowledge the following individuals for their considerable contributions to this study:

Mr. Manuel Pinto and the staff of Clinical Pharmacology Associates for their invaluable help with study conduct and patient recruitment,

Ms. Geraldine Bolden of Merck Research Laboratories for her excellent work in conducting the image analysis of the pupillometry transparencies,

Ms. Mitra Asgary of Merck Research Laboratories for her contribution in analyzing the pharmacokinetic samples, and

Dr. Stephanie Larouche, formerly of Merck Research Laboratories, for her encouragement and scientific guidance."

https://sci-hub.st/https://doi.org/10.1177/009127002237994

here are the author affiliations:

From Merck Research Laboratories, Blue Bell and West Point, Pennsylva-nia, and Terlings Park, United Kingdom (Dr. Guzzo, Ms. Furtek, Dr. Porras,Dr. Chen, Mr. Tipping, Ms. Clineschmidt, Dr. Sciberras, Dr. Hsieh) andClinical Pharmacology Associates, Miami, Florida (Dr. Lasseter).

This study was sponsored by a grant from Merck Research Laboratories, a division ofMerck & Co., Inc.

Dr. Lasseter has no financial interest in Merck & Co. Dr. Sciberras was employed by Merck & Co., Inc., at the time of the study. All other authors are currently employed by Merck & Co., Inc.

Submitted for publication March 5, 2002; revised version accepted June 30, 2002.

Ad-dress for reprints: Ms. Christine Furtek, Merck & Co., Inc., BLX-29, P.O. Box4, West Point, PA 19486.